The reason for different phosphorylation of topoisomerase I in two sublines of L5178Y murine lymphoma (LY cells) was investigated. Camptothecin-resistant LY-S cells show increased poly(ADP-ribose) level and lowered topoisomerase I phosphorylation compared to camptothecin-sensitive LY-R cells. In this study diminished phosphorylation of LY-S topoisomerase I was observed for sites recognized by casein kinase 2 but not for those phosphorylated by protein kinase C. Tryptic digests of LY-S topoisomerase I labeled in vitro by casein kinase 2 indicated that phosphorylation was similarly lowered at different sites. Activity of casein kinase 2 measured in nuclear extracts was about 1.7 times lower for LY-S than LY-R cells. This difference was diminished or eliminated by increasing casein concentration, diluting the extract or increasing the ionic strength. Activity of poly(ADP-ribose) polymerase was 53 times higher in LY-S than in LY-R nuclei. When the activity of the polymerase was inhibited by treatment of LY-S cells with benzamide, casein kinase 2-catalyzed phosphorylation of topoisomerase I increased. This was accompanied by an increase in sensitivity to camptothecin as reflected in the diminished viability of LY-S cells.
Introduction
Topoisomerase I is a target enzyme for the anticancer drug camptothecin (CPT*). Out of several different factors affecting cellular sensitivity to CPT (1) point mutations in topoisomerase I gene resulting in amino acid changes in the protein product (2) (3) (4) (5) and diminished level of topoisomerase I protein (6) are directly linked with topoisomerase I. Another direct reason found by us to be responsible for the reduced sensitivity of topoisomerase I to CPT in LY-S cells was a diminished phosphorylation of the enzyme protein (7) (8) (9) .
In vivo phosphorylation of topoisomerase I is limited to serine residues (10) and is catalyzed by either ck2 (10-12) or PKC (13, 14) . In vitro phosphorylation of topoisomerase I is accompanied by an increase in the relaxing activity (11) (12) (13) and in sensitivity to CPT inhibition (8, 13) . Another modification of topoisomerase I, poly(ADP-ribosylation), inhibits a greater part of the relaxing activity of the enzyme when performed under in vitro conditions (15, 16) .
LY-S cells are an X-ray sensitive (17) subline of murine 'Abbreviations: CPT, camptothecin; BZ, benzamide; ck2, casein kinase 2; DiBr-RB, 5,6-dibromo-l-(P-r>ribofuranosyl) benzimidazole; LY, L5178Y murine lymphoma; PARP, poly(ADP-ribose) polymerase.
lymphoma that are also more CPT resistant (7, 18) than cells of the parental LY-R subline. The two sublines differ also in the content of poly(ADP-ribose) which is ~3 times higher in the LY-S than in LY-R cells (19) . The finding of less phosphorylated topoisomerase I in LY-S cells (7) (8) (9) raised the question of control of the phosphorylation state of this enzyme.
In the present work we show that phosphorylation of topoisomerase I in LY-S cells is controlled by the activity of ck2 which in turn depends on poly(ADP-ribose) level in the cell.
Materials and methods

Cell cultures
LY-R and -S cells were cultured in suspension in Fischer's medium supplemented with 8% heat-inactivated bovine serum. Cells were kept in logarithmic growth phase. They were treated with 2 mM BZ for 5 h. Fraction of dead cells was estimated by dye (nigrosine) exclusion test
Preparation of nuclear extracts and purification of enzymes
Nuclei were isolated according to Pommier et al. (20) and extracted with 0.35 M NaCI according to Estey et al. (21) . Topoisomerase I was purified from the nuclear extract according to Andoh et al. (22) . Ck2 was purified from the nuclear extract of LY cells according to Mills et al. (23) . PKC was isolated from rabbit brains according to Huang and Huang (24) .
Enzymatic assays
The topoisomerase I assay measured the relaxation of supercoiled pBR322 according to Liu (25) . The reaction was quantified by densitometnc scanning of negatives of photographed electrophoretic gels. One unit relaxed 50% of the substrate DNA after 30 min at 30°C. In the ck2 assay the radioactivity introduced into casein from |j-32 P]ATP was measured according to Glover and Allis (26) . One unit represented the amount of enzyme transferring 1 pmol of 32 P to casein/min (26) . PKC activity was determined using PepTag™ Assay (Serva) as described by the producer. PARP activity was determined according to Kasid et al. (16) 
Phosphorylation of isolated topoisomerase I
In vitro phosphorylation of topoisomerase I was performed using either ck2 or PKC as described previously (8) . To be sure that all accessible sites were phosphorylated we repeated the reaction for each sample with doubled amount of enzyme. Samples were electrophoresed, stained with Coomassie Blue and densitometrically scanned to determine the amount of topoisomerase I protein in the sample. Based upon these determinations a standardized amount of topoisomerase I was loaded into gels and further used for autoradiography. In these cases gels were dried and exposed to Kodak films. Autoradiograms were densitometrically scanned.
Electrophoresis
DNA electrophoresis was performed in 0.8% agarose, 2 mM EDTA, 40 mM Tris-acelate (pH 7.8) at I V/cm according to Sambrook et al. (27) . Protein electrophoresis was performed on 7.5% SDS-polyacrylamide gels according to Laemmli (28) .
Tryptic cleavage
The in vitro labeled topoisomerase I was purified, submitted to SDSpolyacrylamide electrophoresis and the 102 kDa band was excised from the gel. Protein was then eluted with 10% methanol and digested with trypsin as described in (10). Tryptic peptides were separated by a high voltage electrophoresis as described in (10).
Results
In vitro phosphorylation of topoisomerase I
The first question addressed in this work was which protein kinase and which phosphorylation sites were responsible for diminished phosphorylation of LY-S topoisomerase I. In previous work (8) we showed that lowered metabolic labeling of LY-S topoisomerase I was accompanied by increased in vitro labeling of accessible sites in the isolated enzyme by exogenous ck2. The latter finding was in contrast to in vitro phosphorylation at the PKC accessible sites examined in this work, which indicated lack of difference between LY-R and LY-S topoisomerase I. The LY-R/LY-S ratio for PKC-catalyzed 32 P incorporation into topoisomerase I was 1.03 ± 0.12 (± SD, n = 4).
To determine whether there was any specific distribution of sites accessible in vitro to ck2 in LY-S but not LY-R, topoisomerase I phosphopeptides resulting from tryptic digestion of both enzymes were analyzed. In each case four main 32 Plabeled peptides were found (Figure 1 ), similarly as previously found for calf thymus (10) and HeLa (29) 
An
compared to LY-R enzyme was similar for each part of peptides (Figure 1 ). These observations indicated that ck2 but not PKC was the kinase responsible for diminished LY-S topoisomerase I phosphorylation and that this effect resulted not from a blocked accessibility of a specific serine residue but rather from a lower efficiency of in vivo phosphorylation which uniformly affected different ck2 sites.
Ck2 activity in nuclear extracts
Looking for a reason for less efficient phosphorylation of LY-S topoisomerase I by ck2 we analyzed the properties of this kinase in nuclear extracts. Ck2 was the prevailing protein kinase activity in the extract isolated from LY nuclei with 0.35 M NaCl. DiBr-RB, which is a specific inhibitor of casein kinases (30), inhibited 90.1 ± 6.7% of 32 P incorporation for the extract from LY-R and 92.9 ±4.1% from LY-S nuclei (± SD, n = 8) at the concentration of 400 |iM. On the other hand, under conditions applied by us no PKC activity was detected in LY nuclear extracts. Taking into account the sensitivity of the used PKC test and the estimated activity of ck2 (see below) one might calculate that the total activity of PKC in the extracts was at least 50 to 100 times lower than that of ck2.
When proteins present in the nuclear extracts were the only substrate for the endogenous ck2, the incorporation of 32 (35) .°M eans ± SD, n = 5.
Phosphorylation of topoisomerase I extracts decreased concomitantly with the increasing amount of casein added to the extract (Figure 2 ). This was in contrast to the reaction performed with purified enzymes. In this case dependence of incorporation of 32 P into casein substrate on the casein concentration was similar for both casein kinases (Figure 2) .
Besides casein concentration we tested for the effects of two other factors on ck2 activity in LY-R and LY-S nuclear extracts: (i) dilution of the extracts with the reaction buffer and (ii) elevation of the ionic strength from commonly used 0.1 M NaCl to 1 M NaCl. Both factors have recently been identified as those affecting ck2 activity due to a change in electrostatic interactions between protomers (31). We found that both factors canceled the difference between ck2 activities in LY-R and LY-S nuclear extracts (Table I) .
It is worth noting that purified ck2 migrated in SDSpolyacrylamide gels as two polypeptides of 43 and 25 kDa, the relative amounts of which were similar in nuclei of both cell sublines (not shown). Both enzymes were similarly inhibited by heparin (75-80% inhibition for both kinases at 0.2 (i.g heparin/ml). Thus, the results presented in this section indicated that the difference between ck2 activities measured in LY-R and LY-S nuclear extracts did not simply reflect a difference in kinase properties. Instead, they pointed to a factor present in the nuclear extract as responsible for the difference.
Effect of BZ treatment on phosphorylation of topoisomerase I in LY-S cells
It has previously been shown that proteins of LY-S cells are more poly(ADP-ribosylated) than those in LY-R cells (19) . In this work we considered an elevated poly(ADP-ribose) content as a possible factor that might affect phosphorylation of topoisomerase I in LY-S cells. Analyzing a possible association between both phenomena we firstly found that the PARP activity was significantly higher in LY-S than in LY-R cells. The LY-S/LY-R ratio between endogenous PARP activities in the nuclear extracts was 5.38 ± 0.76 (± SD, n = 4). To decrease PARP activity in LY-S cells we inhibited it using BZ. BZ and its derivatives did not affect the activity of isolated ck2 (results not shown) but effectively lowered the poly(ADPribose) content in LY-S cells to a level close to that in LY-R cells (19) . We treated LY-S cells with BZ for 5 h, which was long enough both to diminish poly(ADP-ribosylation) (19) and to allow for the establishment of a new phosphorylation level of topoisomerase I (14). Purified topoisomerase I was then 102 kDa contr. +BZ analyzed for its ability to be in vitro phosphorylated by ck2 under conditions which allowed complete phosphorylation of accessible sites (8) .
Treatment of LY-S cells with BZ diminished the ability of isolated topoisomerase I to be phosphorylated by ck2 in vitro. An example of the incorporation of 32 P phosphate into topoisomerase I isolated from LY-S, untreated and previously treated with BZ, is shown in Figure 3 . The amount of 32 P phosphate incorporated into topoisomerase I from BZ treated cells was 0.69 ± 0.07 (± SD, n = 3) times that of the enzyme from the control LY-S cells. This value was close to the LY-S/LY-R ratio of phosphate amounts incorporated in vitro into enzymes from cells not treated with BZ (8) . It indicated that the phosphorylation state of topoisomerase I from BZ-treated LY-S cells was similar to that of the untreated LY-R enzyme.
Cytotoxicity of CPT against BZ-treated LY-S cells
In the previous work (7-9) we have shown that it is the lowered phosphorylation of topoisomerase I that makes LY-S cells less sensitive to CPT. To examine the cellular effects of inhibition of PARP activity we determined the cytotoxicity of CPT in BZ treated cells. As shown in Figure 4 , BZ treatment significantly sensitized LY-S cells to the toxic effects of CPT. 
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Discussion
The results presented in this work indicate that decreased phosphorylation of topoisomerase I in LY-S cells (8) and, consequently, reduced cellular sensitivity to CPT (7) result from impaired ck2 activity. In vitro phosphate groups can be introduced into topoisomerase I either by ck2 (11, 12) or by PKC (13, 14, 32) . Analysis of tryptic phosphopeptides has implicated ck2 as the kinase that phosphorylates topoisomerase I in Novikoff hepatoma cells (33) . It has also been shown that ck2 is physically associated with topoisomerase I in rat liver nuclei (34, 35) . The observation made in this work was that diminished phosphorylation of LY-S topoisomerase I similarly affected different sites recognized by ck2 and did not concern PKC accessible sites. These findings point to ck2 as the kinase responsible for lower phosphorylation of LY-S topoisomerase I. Ck2 activities in extracts isolated from LY-R and LY-S nuclei were found to differ, although the difference was diminished or eliminated by elevated casein concentration, dilution of extracts or increase in the ionic strength. Because the two latter factors affect ck2 activity due to a change in electrostatic interactions (31) , it might be hypothesized that lowered ck2 activity in LY-S nuclei might result from impaired formation of the active enzyme structure. In this context, an especially interesting finding of this work was the association between poly(ADP-ribose) metabolism and topoisomerase I phosphorylation revealed by BZ effect. Poly(ADP-ribose) chains, the level (19) and the structure (36) of which differ in LY sublines, might be considered as a factor affecting formation of active ck2 oligomers. Two other possible mechanisms of the association are as follows, (i) Poly(ADP-ribosylated) proteins might be poor substrates for ck2. Because topoisomerase I is one of the cellular acceptors for poly(ADP-ribose) (15, 16) , its phosphorylation would also be impeded, (ii) Negatively charged poly(ADP-ribose) chains attached to proteins might directly inhibit ck2 activity in the same fashion as heparin (37) . Whether and to what extent each of the above phenomena contributes to the lowered ck2 activity in LY-S cells remains to be established.
The results presented in this work add new elements to the model of CPT resistance of LY-S cells that bases upon the results described in the previous work (7) (8) (9) . The model, presented in Figure 5 , includes the following chain of events: increased PARP activity -» elevated poly(ADP-ribosylation) of proteins -> lowered efficiency of ck2 -» lowered phosphorylation of topoisomerase I -> lowered sensitivity to CPT.
There is growing evidence suggesting that the properties of eukaryotic topoisomerase I are associated with the metabolism of poly(ADP-ribose) (38, 39) . In particular, an inverse relationship between the cellular content of poly(ADP-ribose) and sensitivity to CPT has repeatedly been observed (40,41). The effect of poly(ADP-ribosylation) is commonly attributed to a direct inhibition of topoisomerase I activity (1) . The results of this work show that the effect of poly(ADP-ribosylation) may also occur via topoisomerase I phosphorylation.
